<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04420000</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-MIN-2020-16</org_study_id>
    <nct_id>NCT04420000</nct_id>
  </id_info>
  <brief_title>Effects of Mindfulness Therapy in Patients With Acromegaly and Cushing</brief_title>
  <official_title>Effects of Mindfulness Therapy in Patients With Acromegaly and in Patients With Cushing's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorcio Centro de Investigación Biomédica en Red, M.P.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, multicenter, international clinical trial (one center in Barcelona and one center&#xD;
      in Bergamo, Italy), with exploratory intention.&#xD;
&#xD;
      The main objective of the study will be to assess changes in quality of life, mood, chronic&#xD;
      pain and sleep after the delivery of a Mindfulness program.&#xD;
&#xD;
      The secondary objectives will be: to evaluate if this program also affects blood pressure, if&#xD;
      the changes are maintained six months after treatment and if it determines the decrease in&#xD;
      health resources used.&#xD;
&#xD;
      The intervention group will do Mindfulness sessions according to an established protocol of 8&#xD;
      weeks, while the control group will follow the normal clinical routine. The Mindfulness&#xD;
      protocol will be carried out in group sessions led by a therapist with experience in&#xD;
      mindfulness and compassion, lasting 120 minutes, weekly, which will take place over 8 weeks.&#xD;
&#xD;
      Two separate studies will be done, one for patients with acromegaly which will be the first&#xD;
      to take place and then another for patients with Cushing's syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty patients with acromegaly, (30 in Spain and 30 in Italy) and 60 patients with Cushing&#xD;
      syndrome (30 in Spain and 30 in Italy), who are visited in the Endocrinology services of the&#xD;
      Hospital de la Santa Creu i Sant Pau, Barcelona and Papa Giovanni XXIII in Bergamo will&#xD;
      participate in the study.&#xD;
&#xD;
      In each center there will be 30 patients for each pathology (15 will participate in the&#xD;
      Mindfulness intervention group and 15 will receive the usual treatment).&#xD;
&#xD;
      Inclusion criteria: 1) age between 18 and 70 years, 2) diagnosis of acromegaly, 3) diagnosis&#xD;
      of Cushing's syndrome, 4) patients with controlled disease, 5) not currently participating in&#xD;
      any other clinical study.&#xD;
&#xD;
      Exclusion criteria: 1) physical illnesses or comorbidity of serious mental illness that&#xD;
      impede the practice of Mindfulness, 2) Patients who for cognitive, neurological or&#xD;
      psychiatric reasons could not follow the sessions 3) Patients who do not accept signing the&#xD;
      informed consent 4) Patients with Cushing's syndrome or active acromegaly, 5) Simultaneous&#xD;
      participation in another clinical study.&#xD;
&#xD;
      Patients who meet the inclusion / exclusion criteria will be invited to participate in the&#xD;
      study. The Patient Information Sheet (HIP) and Informed Consent (CI) will be provided. There&#xD;
      will be three evaluation visits (pre and post intervention, and 6 months after the&#xD;
      intervention) in which the participants must complete different questionnaires and scales.&#xD;
      Participants will be invited to keep a daily practice log, and will be required to complete&#xD;
      the assigned daily meditation practices for the 8-week program.&#xD;
&#xD;
      Demographic and clinical variables (collected from the medical history) will be included.&#xD;
      Patients will also have their blood pressure taken before and after each session.&#xD;
&#xD;
      Questionnaires:&#xD;
&#xD;
        -  Quality of Life: AcroQoL (patients with acromegaly), CushingQoL (patients with Cushing&#xD;
           syndrome)&#xD;
&#xD;
        -  Mood: Hospital Anxiety and Depression Scale (HADS)&#xD;
&#xD;
        -  Sleep: Pittsburgh Sleep Quality Index&#xD;
&#xD;
        -  Pain: McGill Pain Questionnaire&#xD;
&#xD;
        -  Self Compassion Scale (SCS)&#xD;
&#xD;
        -  Life satisfaction scale (SWLS)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of life in patients with acromegaly</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>using the Acromegaly Quality of Life Questionnaire (AcroQoL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life in patients with Cushing's syndrome</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>using the Cushing's Quality-of-Life (CushingQOL) questionnaire</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Pain in patients with acromegaly and Cushing's syndrome</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>as evaluated using the McGill Pain Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mood in patients with acromegaly and Cushing's syndrome</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>as evaluate using Hospital Anxiety and Depression Scale (HADS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Sleep in patients with acromegaly and Cushing's syndrome</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>as evaluate using Pittsburgh sleep scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Self compassion in patients with acromegaly and Cushing's syndrome</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>as evaluate using Self Compassion Scale (SCS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Satisfation with life in patients with acromegaly and Cushing's syndrome</measure>
    <time_frame>Baseline, post-intervention (8 weeks)</time_frame>
    <description>as evaluate using SWLS questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Patient Satisfaction</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients having a Mindfulness program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients having a routinary managment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness</intervention_name>
    <description>Mindfulness based programme</description>
    <arm_group_label>Interventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Treatment as usual</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of controlled acromegaly,&#xD;
&#xD;
          -  Clinical diagnosis of controlled Cushing syndrome&#xD;
&#xD;
          -  Must be able to perform Mindfulness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Previous experience with Mindfulness&#xD;
&#xD;
          -  Participation in other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenia Resmini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ciberer and IIB Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugenia Resmini, MD, PhD</last_name>
    <phone>34935537917</phone>
    <email>eresmini@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Resmini Eugenia</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Resmini Eugenia, MD,PhD</last_name>
      <phone>0034651447732</phone>
      <email>resminieugenia@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mindfulness</keyword>
  <keyword>Acromgaly</keyword>
  <keyword>Cushing</keyword>
  <keyword>Quality Of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We'll publish the data after completing the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

